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ABSTRACT
The principal function of the parathyroid hormone (PTH) is maintenance
of calcium plasmatic levels, withdrawing the calcium from bone tissue,
reabsorbing it from the glomerular filtrate, and indirectly increasing its
intestinal absorption by stimulating active vitamin D (calcitriol) produc-
tion. Additionally, the PTH prompts an increase in urinary excretion of
phosphorus and bicarbonate, seeking a larger quantity of free calcium
available in circulation. Two mechanisms may alter its function, limiting its
control on calcium: insufficient PTH production by the parathyroids
(hypoparathyroidism), or a resistance against its action in target tissues
(pseudohypoparathyroidism). In both cases, there are significantly
reduced levels of plasmatic calcium associated with hyperphos-
phatemia. Clinical cases are characterized by nervous hyperexcitability,
with paresthesia, cramps, tetany, hyperreflexia, convulsions, and tetanic
crisis. Abnormalities such as cataracts and basal ganglia calcification
are also typical of these diseases. Treatment consists of oral calcium sup-
plementation associated with increased doses of vitamin D derivatives.
(Arq Bras Endocrinol Metab 2006;50/4:664-673)
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poparathyroidism; PTH resistance; Albright hereditary osteodistrophy
RESUMO
Hipoparatiroidismo e Pseudohipoparatiroidismo.
A principal função do paratormônio (PTH) é a manutenção dos níveis
plasmáticos de cálcio, retirando-o do tecido ósseo, reabsorvendo-o do
filtrado glomerular e, indiretamente, aumentando sua absorção intesti-
nal através do estímulo para a produção de vitamina D ativa (calcitriol).
Além disso, o PTH promove um aumento na excreção urinária de fósforo
e bicarbonato, objetivando uma maior quantidade de cálcio livre
disponível na circulação. Dois mecanismos podem alterar sua função,
limitando seu controle sobre o cálcio: produção insuficiente de PTH
pelas paratiróides (hipoparatiroidismo), ou uma resistência à sua ação
nos órgãos-alvo (pseudohipoparatiroidismo). Em ambos os casos, ocorre
uma redução significativa dos níveis plasmáticos de cálcio em associ-
ação com hiperfosfatemia. Manifestações clínicas características são:
hiperexcitabilidade nervosa, com parestesia, cãimbras, tetania, hiper-
reflexia, convulsões e crise tetânica. Catarata e calcificação dos
gânglios basais são anormalidades típicas dessas doenças. O tratamen-
to consiste da suplementação oral de cálcio, associada com doses ele-
vadas de derivados da vitamina D. (Arq Bras Endocrinol Metab
2006;50/4:664-673)
Descritores: Hipoparatiroidismo; PTH; Hipocalcemia; Pseudo-
hipoparatiroidismo; Resistência a PTH; Osteodistrofia hereditária de
Albright
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HYPOCALCEMIA: CLINICAL MANIFESTATIONS
AND DIFFERENTIAL DIAGNOSIS
SERUM CALCIUM CONCENTRATION is kept within a nar-row physiological range due to complex control
mechanisms involving the parathyroid hormone (PTH),
active vitamin D (1.25(OH)2D), and calcium sensor
receptors, in addition to the concentrations of calcium
and phosphate, which act in the renal, intestinal, and
bone tissues in order to maintain calcium homeostasis.
Hypocalcemia occurs when homeostatic mechanisms
fail or when they are not fully compensated.
The normal range of total serum calcium is
between 8.5 and 10.2 mg/dL (2.12 to 2.55
mmol/L). Symptoms of hypocalcemia occur when the
level of ionized calcium is below 2.8 mg/dL (0.7
mmol/L), equivalent to 7.0 to 7.5 mg/dl (1.75 to
1.87 mmol/l) of total calcium (1,2). The severity of
symptoms and clinical signs of hypocalcemia correlates
with the magnitude and speed at which calcium
declines, influenced by acid-base status and presence
of hypomagnesemia and/or sympathetic hyperactivity.
Acute hypocalcemia
In acute and/or severe symptomatic hypocalcemia there
is a predominance of neuromuscular, neuropsychiatric,
and cardiovascular abnormalities. There is an increase in
neuromuscular excitability, latent or evident, with senso-
ry and motor disruption. Perioral or extremity paresthe-
sia, cramps, myalgia, and muscular weakness are mild to
moderate symptoms. Smooth muscle spasms may cause
biliary and intestinal cramps, dysphagia, bronchospasms,
laryngeal stridor, premature birth, and detrusor muscle
dysfunction. Severe hypocalcemia manifests as sponta-
neous tetany, which may appear in the form of carpope-
dal spasms and, more rarely, laryngospasms. Neuropsy-
chiatric manifestations include irritability, anxiety, psy-
chosis, hallucinations, dementia, depression, mental con-
fusion, and extrapyramidal abnormalities. Increased
intracranial pressure, papilledema, and convulsions can
also be present, and must be differentiated from severe
tetany muscular spasms (3-5).
Typical clinical signs of neuromuscular irritabil-
ity associated with latent tetany include hyperreflexia
and Chvostek’s and Trousseau’s signs, respectively.
Chvostek’s sign is obtained by the percussion of the
facial nerve approximately 2 cm anterior to the ear
lobe, causing contraction of the ipsilateral facial mus-
cles. It has low specificity and sensibility; 25% of
healthy individuals present a positive sign, while 29%
of hypocalcemic individuals present a negative sign.
Trousseau’s sign is more reliable; 94% of hypocalcemic
individuals and only 1 to 4% of healthy individuals pre-
sent a positive sign, which is obtained by pressurizing
a sphygmomanometer approximately 20–30 mmHg
above systolic pressure for 3 minutes. It is character-
ized by carpal spasms, with adduction of the thumb,
followed by flexion of the metacarpophalangeal joint,
extension of the interphalangeal joints, and flexion of
the wrist, creating the classic “obstetrician’s hand”
pose, in addition to causing paresthesia, muscular ten-
sion, and local cramps (6).
Severe hypocalcemia may result in bradycardia or
ventricular arrhythmias, cardiovascular collapse, and
hypotension that is non-responsive to fluids and vaso-
pressors. A decrease in myocardial contractility occurs, as
well as a typical electrocardiographic abnormality, which
is the rate-corrected QT interval (QTc) prolongation.
Chronic hypocalcemia
Patients with chronic hypocalcemia may or may not
have symptoms of discreet neuromuscular irritation,
even with markedly low calcium levels. Asymptomatic
cases may be detected by chance, by the dosage of cal-
cium in routine exams, during periods of greater calci-
um demand (i.e.: gestation, lactation, menstrual cycle
and states of alkalosis), or during the use of hypocal-
cemic drugs (i.e.: bisphosphonates). Ectodermic
abnormalities from dry skin to dermatitis and even
alopecia are common. Dental abnormalities suggest
the time of hypocalcemic onset. In infancy, it may lead
to dental or enamel hypoplasia, the delay or absence of
permanent tooth eruption, an increase in cavity occur-
rence, the shortening of molar roots, and, in some
cases, the loss of all teeth (7).
Significant cognitive deficits, neuropsychiatric
abnormalities, and extrapyramidal symptoms that
resemble Parkinson’s disease or chorea are associated
with the calcification of basal ganglia, which occurs in
all forms of chronic hypocalcemia and may be detect-
ed with greater sensibility using computerized tomog-
raphy (8).
Other findings of chronic hypocalcemia include
sub-capsular cataracts, an increase in bone mineral
density (BMD), and greater susceptibility to dystonic
reactions induced by phenothiazines (4).
Differential diagnosis of hypocalcemia
Ionized or free calcium dosages are quicker, which will
make them more useful during urgent situations.
Hypocalcemia must be confirmed by the measurement
of total plasmatic calcium, which should always be cor-
rected in hypoalbuminemia cases (plasmatic albumin <
4 mg/dL) according to the following formula:
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Corrected Serum Ca= Total Serum Ca mg/dL (0.8 x
[(4 – albumin mg/dL)].
Differential diagnosis of hypocalcemia will
depend largely upon PTH and phosphorus levels, eval-
uated along with other clinical and laboratory data
(table 1). Cases presenting hypophosphatemia should
include differential diagnosis of vitamin D, while cases
associated with hyperphosphatemia are determined
according to PTH levels.
HYPOPARATHYROIDISM
Hypoparathyroidism is an abnormality caused by a
parathyroid hormone (PTH) secretion deficiency, and
encompasses heterogeneous conditions (table 1),
which makes etiological differentiation crucial to the
detection of abnormalities associated with some of
these diseases beforehand, thereby preventing compli-
cations (4). Signs and symptoms are caused by hypocal-
cemia. Laboratory measurements present hypocal-
cemia, hyperphosphatemia, and inappropriately low or
undetectable PTH. Generally, levels of 1.25(OH)2D
are low and the alkaline phosphatase is normal. In the
majority of cases, hypoparathyroidism is sporadic, but
there are familial cases in which transmission may be
autosomic recessive, dominant, or X-linked.
The most common cause of hypoparathy-
roidism is after thyroid surgery. Incidence of perma-
nent hypoparathyroidism varies and depends on the
root disease, extent of surgery, and surgeon’s experi-
ence. Symptoms generally begin 1 or 2 days after the
procedure, and in approximately 50% of the cases this
abnormality is transient and caused by edema or glan-
dular hemorrhage. After the removal of 1 or more
parathyroids for the treatment of primary hyper-
parathyroidism, hypocalcemia indicate 2 etiologies:
Hungry Bone Syndrome or hypoparathyroidism. Dif-
ferentiation is made via measurements of phosphorus,
which will be low in Hungry Bone Syndrome and high
in hypoparathyroidism. Hypoparathyroidism may be a
rare complication after radioactive iodine treatment or
external radiotherapy on the cervical region (9,10).
Autoimmunity may also be another cause of
hypoparathyroidism, which may be isolated or associ-
ated with other autoimmune diseases (11). Antibodies
against parathyroids were detected in more than 30%
of patients with isolated hypoparathyroidism and more
than 40% of patients with hypoparathyroidism associ-
ated with other endocrine deficiencies. Antibodies
against the calcium sensor-receptor (CASR) have been
found in more than 50% of patients with polyglandu-
lar autoimmune syndrome type I or hypoparathy-
roidism associated with autoimmune hypothyroidism.
The polyglandular autoimmune syndrome type I is
characterized by the triad: hypoparathyroidism (which
is the most frequent endocrinopathy), mucocutaneous
candidiasis, and adrenal insufficiency. It is caused by a
mutation in the autoimmune regulator gene (AIRE),
Low PTH levels (hypoparathyroidism)
Parathyroid Destruction
Surgery
Auto-immune (isolated or polyglandular)
Cervical irradiation
Infiltration by metastasis or systemic diseases
(Sarcoidosis, amyloidosis, hemochromatosis,
Wilson’s disease, thalassemia)
Reduced parathyroid function
Hypomagnesemia
PTH gene defects
Calcium sensing receptor mutations
Parathyroid agenesis
DiGeorge Syndrome
Isolated x-linked hypoparathyroidism
Kenny-Caffey syndrome
Mitochondrial neuropathies
High PTH levels (secondary hyperparathyroidism)
PTH resistance
Pseudohypoparathyroidism
Hypomagnesemia
Vitamin D deficiency
Nutritional
Lack of sunlight
Malabsorption
Vitamin D dependent rickets
type I (lack of activity of 1a-hydroxylase)
type II (Vitamin D receptor resistance)
Chronic renal disease
Drugs
Bisphosphonates, cisplatin, ketoconazole, gallium 
nitrate, anticonvulsants
Hyperphosphatemia
Renal insufficiency
Massive tumor lysis
Acute rhabdomyolysis
Acute pancreatitis
Hungry bone
Toxic shock syndrome
Acute severe illness
Calcium chelators (citrated blood transfusions, phosphate)
Table 1. Causes of hypocalcemia.
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located in locus 21q22.3, which produces a protein
that functions as a transcription regulator. This syn-
drome may be sporadic or familial, with autosomic
recessive transmission. Clinical signs begin to appear in
patients approximately 5 years after birth with the
emergence of candidiasis, followed by hypoparathy-
roidism before the age of 10, and later adrenal insuffi-
ciency, found in 100%, 79%, and 72% of the cases,
respectively (11,12). Hypogonadism, hypothyroidism,
insulin-dependent mellitus diabetes, alopecia, vitiligo,
keratoconjunctivitis, intestinal malabsorption syn-
drome, chronic hepatitis, and pernicious anemia may
also be present.
Maternal hyperparathyroidism, which inhibits
PTH secretion by newborns’ parathyroids, is another
cause of hypoparathyroidism. Hypocalcemia general-
ly develops in the third week of life and is self-con-
tained (10). Variations in magnesium levels may also
cause hypoparathyroidism. Hypermagnesemia stimu-
lates the CASR and inhibits PTH secretion. In such
circumstances, the clinical case of neuromuscular
hyperexcitability is usually more discreet. Hypomag-
nesemia, commonly seen in chronic alcoholism and
burn victims, may also cause hypocalcemia because it
promotes the diminution of PTH secretion levels in
addition to causing renal and bone resistance to PTH
action (13).
DiGeorge Syndrome is characterized by thymus
and parathyroid dysgenesis, cardiac malformation, and
facial dysmorphogenesis. There is a defect in the for-
mation of the third and fourth bronchial arches, owed
to the deletions of locus 22q11.2, but the gene
responsible for the syndrome has yet to be identified.
Some patients with phenotype similar to DiGeorge
Syndrome present deletions in other chromosomes
(10p13 and 10p14) (14). The agenesis or dysgenesis
of isolated parathyroids have X-linked or autosomic
recessive transmission. Cases with X-linked transmis-
sion are related to a mutation in locus Xq26-27, which
likely plays a role in the embryological development of
parathyroids (10).
Another genetic cause is HDR Syndrome, char-
acterized by hypoparathyroidism, neuro-sensorial deaf-
ness, and renal dysplasia. HDR is related to haploinsuf-
ficiency or function loss of gene GATA3 (GATA bind-
ing protein 3), located in chromosome 10p14-10,
which belongs to the family of transcription factors
involved in embryological development (15).
Other complex syndromes associated with
hypoparathyroidism are: Sanjat-Sakati syndrome
(hypoparathyroidism, mental retardation, stunted
growth, dysmorphism, and seizures, related to a muta-
tion in the chromosome region 1q43-44); Kenny-Caf-
fey Syndrome (stunted growth, facial-cranial abnor-
malities, long bone cortical thickening, with medullary
stenosis and basal ganglia calcification); mitochondrial
myopathies, such as Kearns-Sayre Syndrome
(encephalomyopathy, oftalmoplegia, retinal pigment
dystrophy and cardiomyopathy) and Pearson’s mar-
row-pancreas syndrome (neutropenia, sideroblastic
anemia, vacuolization of the bone marrow cells, and
exocrine pancreas dysfunction) (10).
Patients classified as having idiopathic
hypoparathyroidism must be carefully evaluated in
order to exclude genetic syndromes. Genetic studies
have linked these cases to mutations in the CASR and
PTH genes. The CASR gene, bound to the G protein
and comprising 1078 amino acid residues, is located in
chromosome 3q and codifies a cell surface receptor
belonging to family C of the seven transmembrane
receptor (7TM) superfamily (16,17). Predominantly
expressed in the parathyroids and kidneys, this recep-
tor regulates PTH secretion and the tubular excretion
of calcium in response to fluctuations in calcium serum
levels. When extra-cellular calcium concentrations
increase, the CASR activates the G protein pathway,
stimulating the activity of phospholipases C, leading to
the accumulation of inositol 1,4,5 triphosphate (IP3)
and the liberation of calcium from intra-cellular stor-
age. The increase of intracellular calcium results in the
activation of protein kinase C, which in turn activates
the MAPK’s pathway, reducing the PTH gene tran-
scription (15-17). The CASR is found in tissues unre-
lated to calcium homeostasis, such as the mammal
gland, keratinocytes, central nervous system, pancreas,
and epithelial cells, although its function has yet to be
defined (16). Mutations that lead to function loss in
this gene are related to familial benign hypocalciuric
hypercalcemia and severe neonatal primary hyper-
parathyroidism (15,17). Activating mutations, on the
other hand, cause a decrease of the calcium set point,
promote the suppression of PTH, and induce hyper-
calciuria, which may aggravate the hypocalcemia.
Mutations are generally located in the aminoterminal
domain of the extra-cellular and transmembrane por-
tions of the CASR. Exons 3, 4 and 7 are considered
hotspots for activating mutations in this gene. Exons 3
and 4 involve the extra-cellular domain, an essential
portion of the receptor for glycosylation, cell surface
expression, dimerization, and binding of the ligand.
Mutations in exon 7 involve domains that participate
in the activation of G proteins associated with the
receptor (18). Lienhardt and colleagues showed a high
frequency of CASR mutations (42%) in patients with
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isolated hypoparathyroidism, placing added impor-
tance on the screening of this gene, especially in
hypocalcemic patients showing normal urinary calcium
excretion (relative hypercalciuria). Since there is an
excellent correlation between the presence of muta-
tion in the CASR and hypocalcemia, the measurement
of the serum calcium may be used as a sufficiently sen-
sitive screening in the affected families with this abnor-
mality (18). Patients are generally asymptomatic, the
serum PTH is normal or low, and they receive the
hypoparathyroidism diagnosis (15). It is important to
distinguish these patients from those with
hypoparathyroidism, because their treatment with cal-
cium and vitamin D may lead to hypercalciuria,
nephrocalcinosis, and loss of renal function (10).
Mutations of the PTH gene, located in locus
11p15, are uncommon causes of hypoparathyroidism,
and they can present autosomic recessive or dominant
modes of inheritance. They result in defective PTH
molecule synthesis and undetectable PTH levels.
Another gene related to hypoparathyroidism is GCMB
(a human gene homologous to the Drosophila glial cell
missing gene b), located in chromosome 6p24.2,
expressed exclusively in the parathyroids, and which
codifies an important transcription factor for the devel-
opment of these glands (10). The Gcm2 (glial cells
missing 2) is the murine gene homologous for GCMB.
Homozygote knockout rats (-/-) for the Gcm2 do not
present parathyroids and develop hypocalcemia and
hyperphosphatemia. PTH levels are normal or low, but
insufficient to control hypocalcemia. In these rats there
may also be PTH production by parathyroid cells locat-
ed in the thymus capsule, explaining the diminished,
but detectable, PTH levels. In humans it is unknown if
there is intrathymic PTH production or if this small
PTH production is due to the gene’s residual activity
(15,19).
PSEUDOHYPOPARATHYROIDISM
The term pseudo-hypoparathyroidism describes a group
of abnormalities characterized by clinical and laborator-
ial hypoparathyroidism findings (hypocalcemia, hyper-
phosphatemia), but with high plasmatic levels of PTH
due to a target tissue resistance, if chronic renal failure
or magnesium deficiency were excluded (20).
Historical
In 1942, Fuller Albright and cols. described 3 patients
with clinical and laboratorial hypocalcemia findings in
which the administration of parathyroid tissue extracts
did not promote an increase in serum calcium or phos-
phaturia (21). These individuals presented develop-
ment abnormalities: rounded face, short stature, obe-
sity, brachydactyly, short and low-set nasal bridge,
strabismus, and ectopic calcifications; which were des-
ignated Albright’s Hereditary Osteodystrophy
(AHO). Due to biochemical similarities with hypo-
parathyroidism, but associated with high levels of PTH
was called pseudo-hypoparathyroidism (PHP). In
1966, Tashjian et al. (22) demonstrated an increase in
serum PTH concentrations in these patients and, in
1969, Chase et al. (23) presented that there was no
urinary AMPc generation in patients with PHP and
the pathogenesis of this abnormality should be related
to a renal defect in the generation of urinary AMPc by
the PTH receptor.
PTH receptor type I
PTH receptor type I is expressed in the kidney and bone
as a glycoprotein of approximately 75 kDa that connects
to both PTH and PTH-related protein (PTHrP). This
receptor, attached to regulatory heterotrimeric protein
G (α, β, γ), presents a single polypeptide chain with
seven transmembrane domains, 3 extracellular loops,
and 3 or 4 intracellular loops (20).
Hormone binding leads to the activation of
protein Gs, with disassociation of subunit α. This,
when activated, disconnects itself from the receptor
and functions as a primary modulator of the adenyl
cyclase, promoting the intracellular formation of cyclic
AMP (AMPc), which rapidly activates the protein
kinase A (PKA) (21-25). The intrinsic GTPase activity
of subunit α permits the linking of βγ dimer for a new
activation cycle.
Patients with AHO present inactivating muta-
tions in the GNAS1 gene, which codifies the subunit
α of protein Gs, mapped in chromosome 20q13.2-
20q13.3. The GNAS1 gene is codified by 13 exons, in
addition to 3 initial exons that correspond to different
promoters, allowing, by alternative splicing, the for-
mation of 4 different isoforms. Exons 2-13 are com-
mon to all transcripts. Mutations were described in all
exons, except in 3, which despite suffering splicing out
still produced a functional protein (26).
Recent studies confirm that the GNAS1 gene
presents the imprinting phenomenon, which explains
the variations in phenotype depending upon the
maternal or paternal mutation’s origin (24,27,28).
Three promoters present opposing models of allele-
specific methylation and monoallelic transcription.
The promoter closest to the 5’ extremity codifies
region NESP55 (neuroendocrine secretory protein
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55), which is expressed exclusively by the maternal
allele, while exons XLαs (extra large as like protein)
and 1A (1 alternative) are expressed by the paternal
allele (figure 1). Despite simultaneous imprinting
(paternal and maternal), expression of Gsα appears to
be biallelic in the majority of examined human tissues,
but expressed maternally in only some tissues such as
the proximal renal tubules (25).
Pathogenesis and classification
The characterization of the molecular bases of pseudo-
hypoparathyroidism began with the observation that
the AMPc is the mediator of various PTH actions in
the kidney and bone fiber.
PTH infusion remains the most consistent test
for the distinction of the diverse variants of this syn-
drome. Based in the abnormalities of the various com-
ponents of the transduction of the cell membrane sig-
nal, the pseudo-hypoparathyroidism may be divided in
distinct forms.
Pseudo-hypoparathyroidism type 1a (PHP1a)
Presents AHO phenotype. There is a reduction in
activity of the stimulatory protein G (Gs), limiting
AMPc synthesis. In this situation, patients are not only
resistant to PTH, but to other peptide hormones like
TSH, gonadotrophins, and glucagon. Transmission is
autosomic dominant (29). Hypocalcaemia and hyper-
phosphatemia are not typically present until five years
of age, but PTH elevations may be documented much
earlier and sometimes are associated with light hyper-
calcemia. Primary hypoparathyroidism frequently pre-
cedes the development of functional hypoparathy-
roidism and may be detected during neonatal screen-
ing. Gonadal dysfunction (hypogonadism or delayed
puberty) is very frequent, especially in women (30).
There are accounts of resistance to GHRH and pro-
lactin deficiency in PHP1a cases (25,31,32). There is
considerable variability in relation to tissue responsive-
ness to Gs protein deficiency, which may also be
explained by the differences in the quantity of AMPc
necessary in order to activate the kinase proteins and
generate physiological responses in each tissue. The
absence of imprinting in other target tissues would be
another explication for patients with PHP1a who do
not develop resistance to other hormones that stimu-
late the Gsα protein and paths linked to the AMPc (for
example: ACTH and vasopressin) (25,26).
Pseudo-hypoparathyroidism type 1b (PHP1b)
Presents normal appearance, normal Gs activity, and
isolated resistance to PTH. Molecular studies do not
show an intrinsic defect in the PTH receptor, and pre-
sent normal Gs function in the erythrocytes (25). The
majority of cases appear to be sporadic, but some
familial cases were described as having autosomic
dominant transmission (29,33). As in PHP1a, a defec-
tive nephrogenic answer to AMPc occurs in relation to
PTH. However, these individuals present elevated
PTH concentrations and frequently manifest skeletal
abnormalities similar to those that occur in patients
with hyperparathyroidism (30). Fibroblast studies
show small accumulation of AMPc in response to PTH
in some cases associated with lower quantities of the
PTH type I Receptor RNAm. A molecular defect was
mapped in a small region of chromosome 20q13.3
(exon 1A) next to the GNAS1 gene. Exon 1A is
important to maintain the tissue-specific imprinting of
Gsα and is normally methylated in the maternal allele
and not methylated in the paternal allele (25). One of
the proposed mechanisms to explain PHP1b cases was
suggested by Weinstein and cols. (figure 2). Exon 1A
contains a cis-acting, negative regulatory element
(silencer) that is both methylation-sensitive and tissue-
specific (25,26). A tissue-specific trans-acting repres-
sor (R) binds to the silencer and suppresses Gs expres-
sion on the paternal allele, but is unable to bind the
maternal allele due to methylation, allowing Gsα to be
expressed from the maternal allele. In the majority of
tissues, exon 1A is methylated but the repressor is not
expressed, and as a result the Gsα is expressed bialleli-
cally. In PHP1b, the methylation of this exon is absent
in the maternal allele, allowing the repressor to link to
both alleles and suppress the Gsα expression in the
renal proximal tubules, raising the Gsα deficiency and
PTH resistance (26,29,34), which normally only
express the maternal allele. These individuals do not
present AHO, because the defective imprinting does
not have an effect in the Gsα expression of the major-
ity of the tissues where it is expressed biallelically.
Figure 1. General organization and imprinting patterns of
the GNAS1 gene. Promoter NESP55 is only expressed by the
maternal allele, while promoters XLαs and 1A are expressed
by the paternal allele.
αs
αs
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Pseudo-hypoparathyroidism type 1c (PHP1c)
Presents Albright’s phenotype and resistance to multi-
ple hormones (PTH, TSH, gonadotrophins, and
glucagon). Gs activity is normal, and so is Gi. Studies
show reduced activity of the membrane’s adenyl
cyclase catalytic subunit. It has yet to be clarified
which molecular defect is responsible (29).
Pseudo-hypoparathyroidism type 2 (PHP2)
Some patients present normal phenotype, normal
AMPc urinary excretion but absent phosphaturic
response to PTH. It is probably associated with defects
in stages posterior to AMPc formation, because Gs
activity is normal. Its defect has yet to be identified
and suggests that there is not any evidence of familial
transmission and that it may be an acquired defect.
Pseudo-pseudohypoparathyroidism (PPHP)
The term was used by Albright to describe patients
with the Albright phenotype, but without the labora-
torial findings (35). Some clinical syndromes, howev-
er, may present the same skeletal abnormalities as
AHO without evidence of PTH resistance. PPHP car-
riers are often times relatives of PHP patients, and may
present periods of hypocalcemia and normocalcemia.
AHO patients who inherit Gsα mutations from their
mothers also develop resistance to TSH, PTH, and
gonadotrophins (PHP1a), while those who inherit it
from their fathers develop only OHA (PPHP). This is
owed to the fact that the Gsα gene is expressed pri-
marily from the maternal allele in target-tissues for the
respective hormones (renal proximal tubules, thyroid,
and ovaries). Mutations in the active maternal allele
lead to Gsα expression deficiency and hormonal resis-
tance, while mutations of the paternal allele have little
or no effect on genetic expression or hormonal signal-
ing (26). The presence of a Gsα allele, however, is not
sufficient in all tissues. Different phenotypes probably
result from tissue-specific combinations of haploinsuf-
ficiency to paternal imprinting (maternal allele expres-
Figure 2. Mechanisms that explain the molecular pathogenesis of PTH resistance (res PTH) and
Albright’s Hereditary Osteodystrophy (AHO) by inactivation and imprinting of the GNAS1 gene. Exon
1A is only methylated in the maternal allele and is transcriptionally active in the paternal allele in all
tissues. In the majority of tissues, exon 1A does not affect Gsα expression, which is biallelically
expressed. In the proximal renal tubules, the non-methylated exon possibly suppresses Gsα expression
in the paternal allele via a repressor (R), leading to a maternal-specific expression of Gsα. In PPHP and
PHP1a, the inactive mutations in the paternal and maternal alleles, respectively, reduce the Gsα
expression by 50%, and this haploinsufficiency produces the Albright phenotype. In the proximal
tubules, mutations in the inactive paternal allele do not affect Gsα expression, while mutations in the
active maternal allele produce PTH resistance. In PHP1b, the methylation defect in the maternal allele
leads to a paternal-specific imprinting model of exon 1A in both alleles. When this happens, Gsα loses
expression in the proximal tubules and there is a PTH resistance, but not affecting the expression in
other tissues, which explains why these individuals do not possess Albright’s phenotype (25).
X
X
X
X
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sion). The AHO phenotype results from deficient sig-
naling in cells in which the Gsα gene is haploinsuffi-
cient but does not suffer imprinting (both alleles are
expressed) (24). The diminution of signaling Gsα
appears to promote osteoblastic differentiation, which
may explain ectopic calcifications and premature clos-
ing of growth plates (25).
Defects outside the endocrine system
Although it is characterized by endocrine dysfunction,
it may have abnormalities in organs whose functions
are mediated by the AMPc path. Weinstock et al. (36)
showed that patients with PHPIA have altered olfac-
tory function if compared with PHPIB patients. The
mental deficiency that occurs 50–75% of PHP-carrying
individuals is also associated with Gs deficiency. Stud-
ies also show evidence of paternal imprinting in the
brown and white adipose tissue, suggesting that obe-
sity may be resultant of decreased Gsα expression in
the adipose tissues, with diminution of the AMPc and
lipolysis formation in response to β-adrenergic stimu-
lus in the adipocyte (25,29).
TREATMENT OF HYPOCALCEMIA
Management of acute or severe symptomatic hypocal-
cemia must be made with intravenous calcium, with
the goal of interrupting symptoms, preventing laryn-
geal spasm, and maintain total calcium levels above
7.0–7.5 mg/dL (ionized calcium greater than 0.7
mmol/L). Hyperphosphatemia, alkalosis, and hypo-
magnesemia, when present, must be corrected. At that
moment, the 10 to 30 mL of 10% calcium gluconate
should be made slowly (10 minutes – maximum of 30
mg/min) in bolus IV (93 to 279 mg of elementary
calcium), and repeated as many times as necessary.
After the grave acute symptoms have been suspended,
a maintenance of calcium levels via continuous
endovenous infusion of 0.5 to 1.5 mg/Kg/h (maxi-
mum of 100 mg/h) of elementary calcium for 4 to 6
hours should be made, using a solution with SG5%
900 ml + 100 ml of 10% gluconate (930 mg elemen-
tary calcium/liter). Serum calcium levels must be mea-
sured frequently in this period, and electrocardio-
graphic monitoring must be done, especially in those
patients using digitalics, due to growing levels or cal-
cium predisposed to digitalis intoxication. Endove-
nous transition to the oral must be made as soon as
possible (2,3,38).
Long-term treatment of patients with chronic
hypocalcemia is done with 1 to 3 g of elementary cal-
cium per day in the various forms of salts available
(table 2). Although calcium carbonate is the most
used salt, it needs gastric acid so that it may be solu-
bilized and absorbed, and causes more collateral gas-
trointestinal effects than other salts. (39). All patients
with hypoparathyroidism or pseudohypoparathy-
roidism who become hypocalcemic must use vitamin
D or analogous in addition to calcium (table 3). The
vast majority of patients obtain control with calcitriol
in dosages of 0.25 µg, taken twice daily, up to 0.5 µg
four times daily. High doses of oral Cholecalciferol
can also be used (50.000 to 150.000 UI/day), but
the risk of intoxication after years of treatment is ele-
vated due to their long half-life. Treatment objectives
are to maintain free ionized calcium levels within the
normal interval, to avoid hypercalciuria, and to sup-
press PTH levels in patients with pseudohypoparathy-
roidism. Hypoparathyroidism causes increased excre-
tion of urinary calcium in relation to serum calcium
and predisposes hypercalciuria, nephrolithiasis, and
nephrocalcinosis. On the other hand, patients with
pseudohypoparathyroidism that have low urinary cal-
cium in relation to serum calcium may tolerate serum
calcium levels within the normal interval without
developing hypercalcemia. Vitamin D intoxication
must be remembered in patients with hypercalcemic
symptoms. Thiazide diuretics are used in cases of
hypercalciuria and nonabsorbable antacid can be
added to reduce hyperphosphatemia and prevent
metastatic calcification. The product of calcium x
phosphate must be kept below 55. Those patients must
have their kidneys radiologically evaluated regularly in
order to rule out nephrocalcinosis (4).
PTH1-34 treatment has the advantage of nor-
malizing calcemia without increasing calciuria, reduc-
ing the risk of nephrocalcinosis and renal insufficiency,
and, theoretically, the antagonists of the calcium sen-
sor receptor may be utilized in the treatment to pro-
mote the inactivation of the receptor and, conse-
quently, increase PTH secretion, but there still have
not been sufficient studies (40).
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